AYTU vs. VAXX, HUGE, COCP, TNXP, NRBO, VBIV, NERV, PIRS, EDSA, and NNVC
Should you be buying Aytu BioPharma stock or one of its competitors? The main competitors of Aytu BioPharma include Vaxxinity (VAXX), FSD Pharma (HUGE), Cocrystal Pharma (COCP), Tonix Pharmaceuticals (TNXP), NeuroBo Pharmaceuticals (NRBO), VBI Vaccines (VBIV), Minerva Neurosciences (NERV), Pieris Pharmaceuticals (PIRS), Edesa Biotech (EDSA), and NanoViricides (NNVC). These companies are all part of the "pharmaceutical preparations" industry.
Aytu BioPharma (NASDAQ:AYTU) and Vaxxinity (NASDAQ:VAXX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, community ranking, institutional ownership, media sentiment, risk, valuation, earnings and dividends.
Aytu BioPharma received 250 more outperform votes than Vaxxinity when rated by MarketBeat users. Likewise, 67.11% of users gave Aytu BioPharma an outperform vote while only 38.46% of users gave Vaxxinity an outperform vote.
Aytu BioPharma currently has a consensus price target of $5.00, indicating a potential upside of 58.73%. Vaxxinity has a consensus price target of $7.00, indicating a potential upside of 6,200.63%. Given Vaxxinity's higher probable upside, analysts clearly believe Vaxxinity is more favorable than Aytu BioPharma.
Aytu BioPharma has a beta of -1.23, suggesting that its stock price is 223% less volatile than the S&P 500. Comparatively, Vaxxinity has a beta of 2.79, suggesting that its stock price is 179% more volatile than the S&P 500.
Aytu BioPharma has higher revenue and earnings than Vaxxinity. Aytu BioPharma is trading at a lower price-to-earnings ratio than Vaxxinity, indicating that it is currently the more affordable of the two stocks.
Vaxxinity has a net margin of 0.00% compared to Aytu BioPharma's net margin of -18.27%. Aytu BioPharma's return on equity of -41.00% beat Vaxxinity's return on equity.
In the previous week, Vaxxinity had 2 more articles in the media than Aytu BioPharma. MarketBeat recorded 2 mentions for Vaxxinity and 0 mentions for Aytu BioPharma. Vaxxinity's average media sentiment score of 0.84 beat Aytu BioPharma's score of 0.00 indicating that Vaxxinity is being referred to more favorably in the news media.
33.5% of Aytu BioPharma shares are owned by institutional investors. Comparatively, 83.0% of Vaxxinity shares are owned by institutional investors. 4.3% of Aytu BioPharma shares are owned by company insiders. Comparatively, 59.1% of Vaxxinity shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Summary
Vaxxinity beats Aytu BioPharma on 10 of the 16 factors compared between the two stocks.
Get Aytu BioPharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for AYTU and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AYTU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aytu BioPharma Competitors List
Related Companies and Tools
